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aortoiliofemoral axis
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Friedrich Duenschede, MD, PhD, and Christian-Friedrich Vahl, MD, PhD, Mainz, Germany
Objective: To analyze early and late mortality, venous morbidity, reinfection, and freedom from reintervention after using
the femoral vein (FV) for vascular reconstruction with infection of the aortoiliofemoral axis.
Methods: By reviewing our database, 86 patients could be identiﬁed with implantation of FV grafts in infected ﬁelds
between November 1995 and July 2012. The patient records were retrospectively analyzed and follow-up information
obtained from patients or their general physician. Seventy-one patients presented with prosthetic graft infection and
15 with an infected aneurysm. For data analysis, patients were divided into an aortoiliac (n [ 67) and a femoral group
(n [ 19). Study end points assessed were early and late mortality, incidence of deep vein thrombosis of the FV donor
limb, graft patency, limb salvage, reinfection, and freedom from reintervention.
Results: Sixty-seven aortoiliac reconstructions were performed using 84 FV grafts with an operative mortality of 9%. After
a mean follow-up of 45 months, survival, patency, limb salvage, and freedom from reintervention were 45%, 97%, 94%,
and 91%, respectively, at 5 years. Twenty FV grafts were employed for 19 femoral reconstructions with an operative
mortality of 10.5%. Here, mean follow-up was 35 months and survival, patency, limb salvage, and freedom from rein-
tervention were 29%, 87%, 93%, and 81%, respectively, at 5 years. Specimen culture conﬁrmed Staphylococcus (epidermidis
and aureus) as the predominant microorganism. Venous morbidity after FV harvest showed an incidence of deep venous
thrombosis of 13.7% for popliteal and 10.6% for tibial level at a follow-up of 24 months with only mild clinical symptoms
(21% limb swelling).
Conclusions: Vascular reconstruction using autologous FV in arterial and graft infection of the aortoiliofemoral axis
provides durable long-term results with acceptable mortality and morbidity. (J Vasc Surg 2014;59:675-83.)Infection of a prosthetic graft is seen as a rare but
devastating complication with an incidence of 0.6%-5%
and conservative treatment is endowed with mortality rates
of 25%-88% and limb loss in 5%-25%.1 Although different
in etiology, infected aneurysms due to microbiological
colonization of an artery2 merge into the same treatment
algorithm as prosthetic graft infections, as both create an
environment of a microbiologically contaminated (in-
fected) operative ﬁeld.3
Results of graft removal and extra-anatomical bypass
for aortoiliofemoral graft infection were disappointing
because of high mortality (up to 27%), inferior patency
(40%-73% at 5 years), high amputation rates (up to 24%),
and the risk of aortic stump blow-out (2%-30%).4 Withthe Division of Vascular Surgery, Department of Cardiothoracic and
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tion, there remains only a limited indication for extra-
anatomical bypass in the treatment of prosthetic graft
infection.5
Currently, several strategies for in situ reconstruction
have emerged, including antibiotic-impregnated grafts,6
silver-coated grafts,7 arterial allografts,8 and creation of a
neoaortoiliac system using autologous femoral vein (FV)
grafts.9
The purpose of this study was to analyze early and late
mortality, venous morbidity, reinfection, and freedom from
reintervention after vascular reconstruction in infected
ﬁelds caused by prosthetic graft infection and infected
aneurysms involving the aortoiliofemoral axis using autolo-
gous FV.
METHODS
The prospectively maintained computerized database
of the Division of Vascular Surgery was reviewed for
patients that received an operation with FV for prosthetic
graft infection or infected aneurysm and the charts of the
retrieved patients were analzyed retrospectively. Patients
or their general physician were contacted for follow-up
information; all living patients were scheduled for clinical
and duplex examination.
From November 1995 until July 2012, a total of 86
patients were retrieved and divided into an aortoiliac and
a femoral group according to the location of the proximal675
Table I. Patient demographics and presentation
Total Aortoiliac Femoral
Mean age 6 SD
(range), years
68 6 10
(46-86)
67 6 9 (46-85) 70 6 12 (46-86)
Sex (male/
female)
60/26 47/20 13/6
Risk factors No. % No. % No. %
Hypertension 60 70 46 73 14 74
Nicotine abuse 38 44 29 43 9 47
Diabetes mellitus 24 28 16 24 8 42
Coronary artery
disease
39 45 31 46 8 42
Renal insufﬁciency
(end stage)
20 (8) 23 16 (6) 24 4 (2) 21
Emergency cases 25 29 18 27 7 37
Presentation
Sepsis 6 8 6 11 0
Bleeding 14 20 9 16 5 31
Aortoduodenal
ﬁstula
6 8 6 11 0
Abscess
(retroperitoneal/
groin)
21 30 18 33 3 19
Groin ﬁstulation 23 33 15 27 8 50
Mean latency
following primary
procedure, months
(range)
79
(5-252)
16
(1-60)
#3 months 18 25 9 16 9 56
>3 months 53 75 46 84 7 44
SD, Standard deviation.
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676 Dorweiler et al March 2014anastomosis (for graft infections) or the most proximal
extension of the infected aneurysm. Throughout the
article, aortoiliac and femoral groups were analyzed sepa-
rately when applicable; however, as both groups represent
distinct entities in terms of perioperative risk, statistical
comparison between both groups was intentionally not
performed. Patient risk factors were deﬁned as follows:
hypertension (controlled with $1 drug), diabetes (oral
antidiabetic medication and/or insulin therapy), nicotine
abuse (active smoking of $1 pack/d), coronary artery
disease (history of $1 vessel disease), renal insufﬁciency
(serum creatinine $2 mg/dL), and end-stage renal disease
(permanent hemodialysis). In addition, operative mortality
was deﬁned as 30-day mortality. The preoperative imaging
algorithm encompassed high-resolution contrast-enhanced
computed tomography (CT) angiogram or contrast-
enhanced magnetic resonance (MR) angiography in sel-
ected cases. In case of duodenal erosion diagnosed by
gastroscopy, groin/retroperitoneal abscess or septic anas-
tomotic erosion, prosthetic graft infection was anticipated.
A complementary ﬂuorodeoxyglucose-positron emission
tomography scan was performed in selected cases in which
only perigraft ﬂuid was present.1 In addition, availability
and quality of the FV and patency of the profunda femoris
vein was examined by duplex ultrasound. A diameter of less
than 6 mm or a chronic occlusion was considered inade-
quate, whereas a short localized duplicature (“biﬁd vein”)
represented no contraindication for use. When a full-
length duplicature was encountered, the larger segment
was employed. In cases where only a portion of the FV
was to be used (femoral replacement), it was harvested
from the proximal third of the FV.
The operative strategy for infected grafts consisted of
complete removal of the prosthetic material and rigorous
debridement and subsequent reconstruction using FV.
FV was prepared using an incision along the sartorius
muscle either simultaneously to (two-team approach) or
following (one-team approach) the preparation of the
infected graft/mycotic aneurysm. After deﬁnitive determi-
nation of conduit length, FV was harvested with ligation of
side branches from the popliteal vein to the deep FV, which
were preserved to ensure collateral ﬂow. FV orientation
was chosen primarily depending on graft caliber. If
adequate size match was possible, the FV graft was
implanted in reversed fashion; otherwise, valve destruction
was achieved by either using a Mills-Valvulotome (in an
earlier series) or by eversion of the vein and complete exci-
sion of the valve leaﬂets.
Microbiology specimens were routinely retrieved intra-
operatively; in cases of prosthetic graft infections, a piece of
the removed graft was additionally sent for culture. Antibi-
otic regimen consisted of calculated broad-spectrum antibi-
otics until the antibiogram was available.
Our anticoagulation regimen encompassed the routine
use of intraoperative unfractionated heparin prior to arterial
clamping (5000 IE). Postoperatively, unfractionated
heparin was continued using a staged-scheme over the ﬁrst
3 days and then adjusting activated partial thromboplastintime to 65-70 seconds at postoperative day 3. For aorto/
iliofemoral reconstructions, anticoagulation was stopped
at discharge and platelet inhibition was continued. For
femorodistal grafts, patients were switched to oral anticoa-
gulation. In cases of postoperative DVT of the FV donor
limb, oral anticoagulation was maintained for 6 months.
The postoperative imaging protocol consisted of CT
scan or MR angiography for all reconstructions as well as
duplex ultrasound of deep veins of the FV donor limb.
Patients were followed clinically and by duplex ultra-
sound (arterial þ venous for FV donor limb) and CT
angiogram/MR angiography in selected cases. For CT
angiogram imaging analysis (two-dimensional maximum
intensity projection and three-dimensional volume
rendering), the OSIRIX software (Pixmeo SARL, Geneva,
Switzerland) was used.
Statistical analysis (Kaplan-Meier) was done using
GraphPad Prism 3 (Graphpad Software Inc, San Diego,
Calif). For patency analysis, the secondary patency is given,
as there was one successful thrombectomy in the femoral
group.RESULTS
We identiﬁed 86 patients with 71 prosthetic graft infec-
tions and 15 infected aneurysms that were located in the
Table II. Indication and replacement strategy
Indication No. Replacement No.
Graft infections Aortobiiliac/-femoral 26 Aortouniiliac/femoral þ femorofemoral crossover (NAIS A) 20
Aortobiiliac (NAIS B) 3
Recanalization þ femorofemoral crossover 3
Aortouniiliac/-femoral 26 Aortouniiliac/femoral 23
Recanalization (contralateral) þ femorofemoral crossover 3
Femorofemoral 5 Femorofemoral 5
Axillobifemoral 3 Aorto/Iliacofemoral þ femorofemoral crossover 2
Femorofemoral (FV) þ axillofemorol (Silver) 1
Femoropopliteal 8 Proximal replacement 8
Femoral 3 Femoral replacement 3
Total 71 71
Arterial infections Abdominal aortic aneurysm 9 Aortic replacement 4
Aortobiiliac (NAIS B) 5
Iliac aneurym 3 Aortouniiliac 3
Femoral aneurysm 3 Femoral replacement 3
Total 15 15
FV, Femoral vein; NAIS, neoaortoiliac system.
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(Table I).
In the aortoiliac group, 49 out of the 55 prosthetic
infections occurred in Dacron grafts (89%), four in polyte-
traﬂuoroethylene grafts, and two in endovascular stent
grafts. In the femoral group, the 16 cases of prosthetic
infections were related to eight Dacron grafts and 8 human
umbilical vein grafts.
Detailed information about the indication for opera-
tion and the procedure is given in Table II. We encoun-
tered six patients with infected aortoiliac grafts (three
aortobiiliac and one aortouniiliac), all implanted for aneu-
rysmal disease, and two bifurcated grafts with an iliac and
a femoral limb, both implanted for occlusive disease. Eight
patients presented with an infected infrainguinal human
umbilical vein graft that, although considered as biological
grafts, contains an outer Dacron mesh and, therefore, can
develop graft infection similar to prosthetic grafts with an
incidence of 3.2%-4.3%.10 The total mean operative time
was 377 6 153 minutes (range, 125-780 minutes);
subgroup analysis for aortoiliac patients revealed 402 6
153 minutes (range, 165-780 min) and 269 6 98 minutes
(range, 125-420 minutes) for femoral patients. Adopting
the classiﬁcation of the neoaortoiliac system initially
proposed by Clagett,11 aortouniiliac reconstruction
combined with femorofemoral crossover bypass (type A,
Fig 1) was performed in 22 cases and aortobiiliac (“panta-
loon” type B, Fig 2) in eight cases. In addition, in three
cases of infected aortouniiliac/-femoral graft, reconstruc-
tion was achieved by recanalization and stenting (bare
metal stent) of the occluded contralateral iliac axis
combined with a femorofemoral crossover bypass.
In this series, a total number of 104 FV grafts were
implanted (Table III). In cases of aortoduodenal ﬁstula,6
omentoplasty was used to separate the duodenum and
to cover the proximal anastomosis. In addition, omento-
plasty was performed in three cases of extensive retroperito-
neal abscess in the absence of aortoduodenal ﬁstula. Inthe femoral group, sartorius muscle transposition was per-
formed in two cases of septic bypass erosion. The microbi-
ological culture of the intraoperative specimen yielded
positive results with single organism in 38 and multiple
organisms in nine cases (Table IV).
For immediate results, both groups are analyzed sepa-
rately. In the aortoiliac group, operative mortality was 9%
(six patients). Three deaths resulted from exsanguination
because of aortic erosion/anastomotic insufﬁciency, and
all three cases had a complicated microbiology spectrum
with candida glabrata (two cases) or multiple organisms
(Bacteroides, Enterobacter, E coli). The other three patients
suffered from ongoing sepsis with subsequent multiorgan
failure: one with extensive para-aortic abscess in a mycotic
aneurysm (Salmonella) together with duodenopancreatec-
tomy for complete erosion of the posterior wall of the
duodenum, one with recurrent duodenal leakage, and
severe peritonitis and one with severe progressive bilateral
lower limb ischemia with secondary bilateral revasculariza-
tion (right femoropopliteal bypass at postoperative day 1
and left femorotibial bypass at day 5). In this patient, above
knee amputation of the left leg was performed because of
bypass occlusion and extensive soft tissue necrosis at post-
operative day 28. In all other patients, limb salvage was
achieved. There were no graft thromboses detected in
the perioperative period. Complications in the aortoiliac
group included hematoma needing operative evacuation
in 11 cases (16%) and percutaneous CT-guided abscess/
drainage in one patient. There were six revisions for
duodenal leakage in four patients, and ischemia of the
colon and the gluteal muscle occurred in one (with subse-
quent colon resection) and two patients, respectively.
Systemic complications included renal insufﬁciency with
temporary hemoﬁltration/dialysis in four patients and
pneumonia/acute respiratory distress syndrome with pro-
longed ventilator dependence in four cases. Five femoro-
distal bypasses for acute lower limb ischemia were
performed in four patients.
Fig 1. Neoaortoiliac system type A. Preoperative computed tomography (CT) scan of a 67-year-old patient with graft
infection 80 months after implantation of an aortobifemoral Dacron graft with perigraft ﬂuid (A) and right groin
abscess/ﬁstulation (C). Complementary ﬂuorodeoxyglucose-positron emission tomography shows corresponding
enhancements (red arrows, B and D). Following complete graft removal, reconstruction by right aortofemoral bypass
combined with femorofemoral crossover bypass (both femoral vein [FV]) was performed (E, three-dimensional
reconstruction of postoperative CT scan). At 69 months of follow-up, neoaortoiliac system is patent with slight
elongation of the femorofemoral graft (F, three-dimensional reconstruction).
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(two patients). One died from multiorgan failure due to
severe pneumonia (candida), the other patient died from
cardiac insufﬁciency because of acute myocardial infarction.
There was one graft thrombosis with subsequent successful
thrombectomy and no major amputations during the early
postoperative period. Complications in the femoral group
included hematoma in four cases (21%) as well as secondary
healing of the groin incision in three cases.
Follow-up information could be retrieved for all
patients; there were no patients lost. The mean follow-up
period was 45 months (range, 1-187 months) for the aor-
toiliac and 35 months (range, 1-129 months) for the
femoral group. Kaplan-Meier analysis showed a median
survival of 42 months for the aortoiliac and 32 months
for the femoral group with a survival rate of 45% and
29% at 60 months, respectively (Fig 3). There were three
late graft occlusions resulting in a secondary patency of
97% and 87% at 60 months, respectively (Fig 4). Four
major amputations in the aortoiliac and one in the femoral
group accounted for a limb salvage rate of 94% and 93% at
60 months, respectively (Fig 5). Two amputations had to
be performed as a consequence of graft occlusion; two
amputations in the aortoiliac group were necessary because
of ongoing gangrene despite patent grafts. Secondaryreinterventions were necessary in four patients of the aor-
toiliac group (three patch plasties and one percutaneous
dilatation for anastomotic stenoses) and one patient in
the femoral group (patch plasty). Together with the
thrombectomies for graft occlusion, rates of freedom
from reintervention of 91% and 81%, respectively, were
noted at 60 months (Fig 6). All surviving patients received
long-term antibiotic treatment for 6 weeks according to
the antibiogram of the isolated microorganisms. In patients
with negative culture, oral broad-spectrum antibiotics
(gyrase inhibitor þ clindamycin) were administered. With
this regimen, no persistence of infection in surviving
patients was evident.
In addition, we separately analyzed the outcome of
patients with negative microbiological culture. For the
femoral group, four patients had negative culture, and all
of them had an uneventful postoperative course and
follow-up period (18, 21, 64, and 91 months). For the aor-
toiliac group, we observed two (6%) deaths, one in a patient
with infected aortobifemoral graft and aortoenteric ﬁstula
with repetitive duodenal ﬁstulation and one in a patient
with infected aortobifemoral graft and secondary severe
lower limb ischemia. Five complications were noted (two
hematoma, one pneumonia, two intermittent hemoﬁltra-
tion), and in the follow-up period, no graft occlusions
Fig 2. Neoaortoiliac system type B. Preoperative computed tomography (CT) scan of a 68-year-old patient with
contained rupture of an infected abdominal aortic aneurysm (A-C). Postoperative magnetic resonance angiography
after implantation of a neoaortoiliac system using two femoral vein (FV) grafts conjoined at the infrarenal aorta (D,
three-dimensional reconstruction). At 38 months of follow-up, both grafts are patent (E, three-dimensional
reconstruction).
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ventions (patch at 24 months, angioplasty at 164 months)
occurred, with a survival rate of 86% at 1 year and 67% at 2
years.
The majority of patients in the aortoiliac group
received platelet inhibition (acetylsalicylic acid [ASA],
n ¼ 36). Two patients were on dual platelet inhibition
(ASA, clopidogrel) as a consequence of coronary stenting
in coronary artery disease. One patient received low molec-
ular weight heparin for hemodialysis, and 12 patients
received oral anticoagulation because of concomitant fem-
orodistal bypass or atrial ﬁbrillation. In the femoral group,
of the eight patients with femorodistal bypass grafts, six
were on oral anticoagulation and two on low molecular
weight heparin for hemodialysis. The patients with femoral
interposition grafts and femorofemoral crossover grafts
received ASA.
For the assessment of venous morbidity of the donor
leg, a subgroup of 67 patients were analyzed who had
received at least three duplex scans of the venous system
(preoperative, early, and late postoperative) (Table V).
The incidence of total deep venous thrombosis following
FV harvest was 9.9% and 3.9% for popliteal and tibial veins,
respectively, and 14.0% and 17.7% for partial popliteal and
tibial vein thrombosis, respectively. The results indicate
that approximately one-half of the total popliteal and tibial
vein thromboses recanalyzed, and one-half of the partial
vein thromboses completely resolved. Clinically, there
were no patients in stage C4-6 of chronic venousinsufﬁciency according to the CEAP classiﬁcation.
However, four patients had moderate swelling of the lower
limb, which matches the four cases of permanent popliteal
vein thrombosis necessitating the use of compression stock-
ings. Ten patients had mild swelling of the lower limb but
were not wearing stockings.
DISCUSSION
The concept of using lower extremity veins for recon-
struction of infected aortoiliofemoral grafts has been simul-
taneously introduced in 1993 by Clagett11 and
Nevelsteen,12 and both groups generated the two largest
series of cases with long-term results published so
far.13,14 In addition, Ehsan reported a 10-year experience
with 46 cases (19 aortic) of graft infections and infected
aneurysms.15 Smaller series encompassed contributions of
seven to 16 cases.16-20
In our institution, we started to use FV as conduit for
reconstruction of infected grafts in 1995 and reported our
preliminary data of seven patients (three aortic) in 2001.21
With an operative mortality of 9%, our results in the aor-
toiliac group are in line with those of Daenens (8%)13
and Ali (10%).14 Perioperative morbidity encompassed an
increased revision rate for hematoma/bleeding in 16%
(5%-8% in 13-14). This may be inﬂuenced by our antico-
agulation regimen with intravenous heparinization to
prevent deep vein thrombosis in the FV donor limb. We
were not able to reproduce the relatively high rate of fas-
ciotomy of 25% reported by Ali.14 In fact, only one of
Table III. Femoral vein (FV) grafts implanted
Total % Aortoiliac % Femoral %
Number total 104 84 20
Harvest
Bilateral 18 21 17 25 1 5
Unilateral (ipsilateral) 31 36 24 36 7 37
Unilateral (contralateral) 23 27 18 27 5 26
For femorofemoral crossover grafts
Unilateral/ipsilateral to inﬂow site
9 16 5 12 4 32
For femorofemoral crossover grafts
Unilateral/contralateral to inﬂow site
5 3 2
Graft orientation
Nonreversed (Mills-Valvulotome) 8 8 8 10 0 0
Nonreversed (eversion and resection) 47 45 41 49 6 30
Reversed 49 47 35 41 14 70
Position of reversed graft (proximal
anastomosis)
49 100 29 (10 aortic
(5 NAIS B), 19 iliac)
60 20 40
Length, mean 6 SD (range), cm 21 6 6 (7-30) 21 6 5 (8-30) 18 6 8 (7-30)
NAIS, Neoaortoiliac system; SD, standard deviation.
Table IV. Microbiology results of prosthetic and arterial
infections (n ¼ 86 patients)
Total Aortoiliac Femoral
Staphylococcus epidermidis (CNS) 13 11 2
MRSA 8 3 5
Staphylococcus aureus 7 3 4
Eschericia coli 7 4 3
Corynebacterium spec. 4 4 0
Enterococcus faecium 3 2 1
Pseudomonas aeruginosa 2 1 1
Salmonella typhimurium 2 2 0
Salmonella enteriditis 2 2 0
Streptococcus bovis 2 2 0
Proteus mirabilis 2 2 0
Bacteroides fragilis 2 2 0
Candida glabrata 2 1 1
Morganella morgagnii 1 0 1
Citrobacter koseri 1 0 1
Acinetobacter iwolﬁi 1 1 0
Klebsiella pneum. 1 1 0
Enterobacter cloacae 1 1 0
Bacillus cereus 1 1 0
Listeria monozytogenes 1 1 0
Single organisms 38 28 10
Multiple organisms (up to 4) 9 6 3
Sterile 37 33 4
Leukocyteþ 3 3 0
CNS, Coagulase-negative Staphylococcus; MRSA, methicillin-resistant
Staphylococcus aureus.
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ischemia with subsequent bilateral femorodistal bypass.
Our late results after a mean follow-up of 45 months
showed a median survival of 42 months corresponding to
a survival rate of 45% at 60 months. This is in the range
of the survival rate observed by Ali (52.4%)14 but consider-
ably less than the 70% and 60% observed at 60 months
by Ehsan and Daenens, respectively.13,15 However, our
patient demographics compared well with that in the study
of Ali,14 whereas Ehsan and Daenens13,15 did not reportdetailed patient demographics to allow comparison of
comorbidity with our patients. There were no perioperative
graft thromboses, a ﬁnding also made by Ehsan,15 and only
one graft occlusion in the long-term, resulting in
a primary/secondary patency of 97% at 5 years. Our limb
salvage rate of 94% at 5 years also compared well with
that observed by Ali (89%), Daenens (98%), and Ehsan
(96%).13-15 We observed the need for reinterventions due
to graft stenoses in four patients (16.8%), resulting in
a rate of freedom from reintervention of 91% at 5 years.
Ehsan reported graft stenoses in 24%,15 Ali in approxi-
mately 9%,14 and Daenens in only 4%.13 Of note, we
have not encountered aneurysmal dilatation of an FV graft
so far, a ﬁnding also made by Daenens13 and Ali.14 Finally,
in all surviving patients, eradication of infection could be
achieved, supported by a targeted antimicrobial regimen
of broad-band oral antibiotics administered for 6 weeks
postoperatively. For the femoral group, the operative
mortality was 10.5%. The rate of perioperative hema-
toma/bleeding was 21%. For the late results, the mean
follow-up period was 35 months with a median survival
of 32 months and a survival rate of 29% at 5 years. This
survival rate is rather disappointing; however, it may be
a sequelae of the increased patient comorbidity (age, dia-
betes) and acuity of presentation (emergency cases, acute
bleeding). This is corroborated by Ehsan who also found
a reduced survival for the nonaortic (femoral) group15
and Schulman, who found a reduced survival of the FV
group of 47% at 5 years compared with 61% for patients
receiving saphenous vein grafts in a randomized study in
primary femoropoliteal bypass grafting.22 However,
a patency rate of 87%, a limb salvage rate of 93%, and
a freedom from reintervention of 81% at 5 years in our
study represent a favorable result for this patient group.
As removal of the FV may constitute a major distur-
bance of the venous drainage of the limb, we performed
a detailed analysis of venous morbidity of the FV donor
limb. Here, an incidence of total vein thrombosis of
Fig 3. Kaplan-Meier analysis for survival. SEM, Standard error of
the mean.
Fig 4. Kaplan-Meier analysis for patency (secondary patency).
SEM, Standard error of the mean.
Fig 5. Kaplan-Meier analysis for limb salvage. SEM, Standard
error of the mean.
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17.7% for popliteal and calf veins, respectively, was noticed.
This is in line with other studies reporting an incidence of
postoperative DVT of 22% of the donor limb.23 In our
study, we could document a thrombus resolution in
approximately 50% of cases during a mean follow-up of
24 months. This is clearly above the resolution rate of
11% observed by Wells23 and may be due to the fact,
that in our study, patients with postoperative lower limb
DVT received oral anticoagulation for 6 months. This
duplex ﬁnding translated into a total rate of FV donor
limb swelling of 21%, which again is in line with the dataobtained by Wells who observed a rate of approximately
30% for donor limb edema.23 However, 15% of our
patients showed only mild swelling without the need for
further therapy, whereas 6% exhibited moderate swelling
that prompted the use of compression stockings.
The contemporary mainstays of conduits in infected
ﬁelds include allografts, and silver-coated and antibiotic-
bonded prosthetic grafts. Summarizing the results of the
three large series with allografts in infrarenal aortic graft
infection, operative mortality ranged from 6%-20%,24-26
and late complications (dilatation/thrombosis) were noted
in 35% for fresh allografts 24 and 0%-1.8% for cryopreserved
allografts.25,26 In the light of the major drawback of allo-
graft acquisition and availability, current recommendations
limit allograft use to institutions with an in-hospital allo-
graft bank and cases with complex surgical situations (ie,
aortoenteric ﬁstulae).8 In contrast to allografts, the silver-
coated vascular prosthesis is readily available; however,
there is still no high level of evidence for the effectiveness
of such grafts.8 Currently, three studies are available
addressing this issue with only limited sample sizes of
11-27 patients27-29 reporting an operative mortality of
11%-21%, respectively, and a late reinfection rate of
7%-18%, respectively.27-29 Aortic reconstruction with
rifampin-soaked Dacron grafts has been proven to be clin-
ically effective with operative mortality rates of 7%-21%,
survival rates of 50%-59% at 5 years, and a rate of reinfec-
tion of 4%-22%. Nonetheless, the success of the technique
relies on adjuvant modalities like omental wrapping.6,30
Taken together, we have shown that vascular recon-
struction in infected aortoiliofemoral ﬁelds with use of
FV has a mortality of 9%-10% with a negligible rate of
late complications (graft stenosis, thrombosis, and dilata-
tion), that venous morbidity after FV harvest is well tol-
erted and that our ﬁndings are in good concordance with
Fig 6. Kaplan-Meier analysis for freedom from reintervention.
SEM, Standard error of the mean.
Table V. Venous morbidity after femoral vein (FV)
harvest
n ¼ 67
Mean age, years 69, 7 6 12 Range, 11-88
Sex (male/female) 42/25
No. %
Thrombosis total/partial
Preop
CFV 0/0 0/0
POP 0/0 0/0
TIB 0/0 0/0
Postop
CFV 0/2 0/2.8
POP 7/10 9.9/14.0
TIB 2/9 3.9/17.70
Follow-up, months Mean, 24 Range, 1-95
CFV 0/1 0/1.4
POP 4/6 5.5/8.2
TIB 1/5 1.7/8.9
CEAPa
C3 (mild) 10 15
C3 (moderate) 4 6
C4 0 0
C5-6 0 0
CFV, Common femoral vein; POP, popliteal vein; TIB, tibial vein.
aCEAP classiﬁcation: C3, edema; C4, pigmentation/lipodermatosclerosis;
C5-6, ulcers.
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682 Dorweiler et al March 2014the results obtained by the other three leading institutions
who advocate this technique.13-15 Furthermore, autolo-
gous reconstruction using FV offers the speciﬁc beneﬁt of
only limited need for antibiotic treatment (4-6 weeks)
with lowest rate of reinfection and late mortality when
compared with prosthetic graft and allografts.5At our institution, operative decision for autologous
reconstruction involves presence of sufﬁcient length of
FV and adequate patient ﬁtness as judged by age, comor-
bidities, and life expectancy. In rare cases where FV is
not available, our second choice is use of biological material
(tube constructed from bovine pericardium patch, 8 mm
Omniﬂow II ovine collagen graft; Bio Nova International
Pty Ltd, North Melbourne, Australia) for reconstruction
of the aorta/iliac axis. Our third choice is antibiotic-
soaked or silver-impregnated Dacron grafts. Due to limited
availability and potential risk of degeneration, we have
refrained from using arterial homografts for infrarenal/iliac
reconstruction at our institution. We consequently attempt
anatomic/in situ reconstruction at the aortic/iliac level, if
necessary using second-choice conduits to prevent the
devastating complication of aortic/iliac stump blow-out
which has been reported after stump ligation.
Limitations of our study can be seen in the retrospec-
tive nature of the analysis, the long interval of patient
recruitment, and the considerable heterogenicity of
methods applied for arterial reconstruction. However,
this shortcoming is also encountered by other groups and
is related to the fact that arterial and graft infections are
a rare and complex entity and the reconstruction has to
be tailored to the individual patient. Additional limitations
arise from the evolution of surgical technique (complete
excision of vein valves) during the study period and the
relatively low number of patients in the femoral subgroup.
However, the ﬁnal decision of treatment strategy in
this complex and highly demanding area is in the hands
of the vascular surgeon and must be tailored to the indi-
vidual patient’s situation, the local availability of graft mate-
rial, and the surgical expertise.AUTHOR CONTRIBUTIONS
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